Research programme: oncology vaccines - Theravectys

Drug Profile

Research programme: oncology vaccines - Theravectys

Alternative Names: THV 02

Latest Information Update: 20 May 2015

Price : $50

At a glance

  • Originator THERAVECTYS
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult T-cell leukaemia-lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Adult T-cell leukaemia-lymphoma; Cancer

Most Recent Events

  • 14 Apr 2015 THERAVECTYS and the Curie Institute agree to co-develop oncology vaccines under a long-term R and D alliance
  • 04 Feb 2015 THV 02 receives Orphan Drug status for Adult T-cell leukaemia-lymphoma in European Union
  • 26 Jan 2015 Preclinical trials in Adult T-cell leukaemia-lymphoma in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top